In addition, many groups have shown that mutations or deletions of TP53 are significantly associated with loss of chromosome 5 or del(5q) in myeloid malignancies.[27–31] It may be that mutation, deletion, or modulation of TP53 is required for low-risk MDS cells with increased apoptosis to progress to high-risk MDS or secondary AML. Here, TP53 is linked to myelodysplastic syndrome.